In SCLC however where BRCA mutations are rare (1–3.5% [9, 43]), we have previously shown that resistance to PARP inhibition to be correlated to activation of the PI3K/mTOR pathway [5]. The gene discussed is PARP1; the disease is small cell lung carcinoma.